Does targeted therapy treat gastrointestinal stromal tumour?

Gastrointestinal stromal tumour, also called GIST, may carry a change in a tumour gene that produces an overactive growth signal. A targeted medicine is selected to interfere with that signal. This approach differs from treatments that act broadly on rapidly dividing cells.

Treatment may be considered before surgery to shrink or control a tumour, after surgery when the team wants to lower the chance of the tumour returning, or when disease cannot be removed completely or has spread. The medicine and treatment plan depend on the tumour's gene changes, location, size, symptoms, and response over time.

Doctors monitor scans, symptoms, blood tests, and possible medicine effects. A treatment can be adjusted or changed if the tumour stops responding or side effects become difficult to manage.

Ask whether the tumour sample has had molecular or mutation testing, because the result can guide the targeted medicine. Bring a list of medicines, supplements, and existing health conditions to the oncology visit. Discuss the purpose of treatment, how response will be checked, and what to do about a missed dose or new symptom.

Take the medicine exactly as prescribed and do not stop it without speaking with the oncology team. Keep a record of symptoms such as nausea, diarrhoea, swelling, skin changes, unusual tiredness, or changes in appetite so the team can respond early.

Contact the oncology team promptly for persistent vomiting or diarrhoea, inability to keep fluids down, marked weakness, new swelling, yellowing of the skin, unusual bleeding, or a rapidly worsening rash. Seek urgent medical help for severe breathing difficulty, chest pain, fainting, confusion, or heavy bleeding.

Which tumour test results guide my targeted treatment? What is the aim of this medicine in my situation? How will scans and blood tests show whether it is working? Which side effects should I report the same day? Are there medicines or foods I should avoid?